HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19.

Abstract
Most SARS-CoV2 infections will not develop into severe COVID-19. However, in some patients, lung infection leads to the activation of alveolar macrophages and lung epithelial cells that will release proinflammatory cytokines. IL-6, TNF, and IL-1β increase expression of cell adhesion molecules (CAMs) and VEGF, thereby increasing permeability of the lung endothelium and reducing barrier protection, allowing viral dissemination and infiltration of neutrophils and inflammatory monocytes. In the blood, these cytokines will stimulate the bone marrow to produce and release immature granulocytes, that return to the lung and further increase inflammation, leading to acute respiratory distress syndrome (ARDS). This lung-systemic loop leads to cytokine storm syndrome (CSS). Concurrently, the acute phase response increases the production of platelets, fibrinogen and other pro-thrombotic factors. Systemic decrease in ACE2 function impacts the Renin-Angiotensin-Kallikrein-Kinin systems (RAS-KKS) increasing clotting. The combination of acute lung injury with RAS-KKS unbalance is herein called COVID-19 Associated Lung Injury (CALI). This conservative two-hit model of systemic inflammation due to the lung injury allows new intervention windows and is more consistent with the current knowledge.
AuthorsRafael B Polidoro, Robert S Hagan, Roberta de Santis Santiago, Nathan W Schmidt
JournalFrontiers in immunology (Front Immunol) Vol. 11 Pg. 1626 ( 2020) ISSN: 1664-3224 [Electronic] Switzerland
PMID32714336 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2020 Polidoro, Hagan, de Santis Santiago and Schmidt.
Topics
  • Acute Lung Injury (immunology, pathology, therapy)
  • Betacoronavirus (immunology)
  • COVID-19
  • Coronavirus Infections (immunology, pathology, therapy)
  • Humans
  • Lung (immunology, pathology)
  • Pandemics
  • Pneumonia, Viral (immunology, pathology, therapy)
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome (immunology, pathology, therapy)
  • Systemic Inflammatory Response Syndrome (immunology, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: